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A B S T R A C T
In patients with chronic coronary artery disease (CAD) and good left ventricular 
function, percutaneous coronary intervention (PCI) does not confer any clear benefit 
in terms of hard long-term clinical outcomes, such as mortality, myocardial infarction 
or the need for subsequent revascularization, as compared with medical conservative 
treatment. Indeed, a meta-analysis of early data from 6 randomised controlled trials 
has showed convincingly that PCI improves anginal symptoms compared to conserva-
tive management, but there has been limited evidence on the effect of PCI on hard 
clinical outcomes. At the same time, the early fear of increased need for revascular-
ization after PCI is probably not warranted. By comparing the benefits against cost 
considerations, it seems that many percutaneous interventions that are currently per-
formed in patients with non-acute CAD are probably not justified.
I N T R O D U C T I O N
Significant coronary stenoses in patients with ischemic heart disease represent an 
established indication for revascularization. In longitudinal studies on patients with 
known or suspected coronary artery disease (CAD), positive thallium 201 studies pre-
dict a significantly higher overall mortality, cardiac death or myocardial infarction,1,2 
whereas scintigraphy studies identify patients with a good prognosis at a low risk for 
future cardiac events.3 However, the possible benefits and consequently indications of 
percutaneous coronary intervention (PCI) in the management of stable patients with 
CAD in non-acute settings have been debated for more than a decade. A meta-analysis 
of early data from 6 randomised controlled trials had showed convincingly that PCI 
improves anginal symptoms compared to conservative management,4 but there has 
been limited evidence on the effect of PCI on hard clinical outcomes, such as the risk 
of death, myocardial infarction (MI) and subsequent revascularization.
E V I D E N C E  F R O M  R A N D O M I Z E D  S T U D I E S
We have recently performed a meta-analysis of all randomized trials comparing 
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PCI to conservative treatment in patients with stable CAD.5 
We identified 11 eligible randomized trials with pertinent 
data.6-20 These were the Second Randomized Intervention 
Treatment of Angina (RITA2) trial, the Angioplasty Com-
pared to Medicine (ACME) study group with two separately 
enrolled strata on single-vessel and two-vessel disease (des-
ignated here as ACME 1 and ACME 2, respectively), the 
Atorvastatin versus Revascularization Treatment (AVERT) 
trial, the Medicine, Angioplasty, or Surgery Study (MASS), 
and Medicine, Angioplasty, or Surgery Study II (MASS II) 
trial, a trial conducted by the Arbeitsgeneinschaft Leitende 
Kardiologische Krankenheusartzte (ALKK) group, and trials 
by Dakik et al, Sievers et al., Hambrecht et al., and Bech et 
al. Patient and disease characteristics are shown in Table 1. 
Mostly patients with single-vessel or two-vessel disease were 
included, but a considerable proportion of patients in MASS 
II had three-vessel disease. The large majority of patients had 
at least some anginal symptoms, but some trials included also 
a few patients without symptoms (Table 1). The reported aver-
age left ventricular ejection fraction was <60% in only one 
trial that lowered the eligibility threshold for ejection fraction 
to 35% (mean 46%).17
R E S U L T S  O F  M E T A - A N A L Y S I S
A total of 2,950 patients were included in the meta-analysis 
(1,476 receiving PCI and 1,474 receiving conservative treat-
ment). There were a total of 196 deaths (PCI arm n=95 vs. 
conservative arm n=101), 235 patients had cardiac death or 
Table 1. Patient and Disease Characteristics in the Eligible Studies
Study
Sample Age Male DM Prior MI No symptoms LVEF F/U
MT/PCI mean (yrs) (%) (%) (%) (%) (%) (years)
RITA 2 514/504 58 median 82 9 47 20 ND* 7
ACME 1 115/112 60 100 18 31 9 68 2.4-5
ACME 2 50/51 60 100 18 41 18 67 2.4-5
AVERT 164/177 59 84 16 42 16 61 1.5
Dakik 22/19 53 59 ND 100 0 46 1
MASS 72/72 56 58 18 0 0 76 5
MASS II 203/205 60 68 30 41 ND 67 1
ALKK 151/149 58 87 16 100 0 ND† 4.7
Sievers 44/44 56 ND 0 55 ND ND 2
Hambrecht 51/50 61 100 23 46 0 63 1
Bech 91/90 61 64 12 25 0 65 2
CAD: coronary artery disease; DM: diabetes mellitus; EF: ejection fraction; F/U= follow-up; MI: myocardial infarction; MT: medical treatment; 
PCI: percutaneous coronary intervention; ND: no data available. See text for trial name abbreviations.
The ACME trial consists of two separately enrolled strata of patients with single-vessel (ACME 1) and two-vessel (ACME 2) disease.
*93% of the patients had very good or excellent wall motion score
Adapted from Katritsis et al (reference 5).
suffered an MI (PCI arm n=126 vs. conservative arm n=109), 
and 153 patients had non-fatal MIs (PCI arm n=87 vs. con-
servative arm n=66), while 215 patients underwent coronary 
artery bypass grafting (CABG) (PCI arm n=109 vs. conserva-
tive arm n=106) and 462 had PCI during follow-up (PCI arm 
n=219 vs. conservative arm n=243).
There was no significant difference between the two 
treatment strategies regarding mortality, cardiac death or 
MI, non fatal MI, and CABG or PCI during follow-up. By 
random effects, the risk ratios (95% confidence intervals) 
for the PCI vs. conservative treatment arms were 0.94 (0.72-
1.24), 1.17 (0.88-1.57), 1.28 (0.94-1.75), 1.03 (0.80-1.33), and 
1.23 (0.80-1.90), for these 5 outcomes, respectively (Table 2). 
The summary estimates showed no difference between PCI 
and conservative treatment in the mortality risk and the 95% 
confidence intervals clearly excluded relative risk differences 
of 28% (Figure 1a). If anything, there was a trend for more 
cardiac deaths or MIs, in particular non-fatal MIs (Figure 
1b), in patients who underwent PCI, with the point estimate 
suggesting approximately a 30% increase in the relative risk 
of non-fatal MI with PCI. A possible survival benefit was seen 
for PCI only in trials of patients who had a relatively recent MI 
(risk ratio 0.40, 95% confidence interval 0.17-0.95). Except for 
PCI during follow-up, there was no significant between-study 
heterogeneity for any outcome.
There was absolutely no difference in the need for CABG 
between the two compared treatment strategies (Table 2). 
The 95% confidence intervals also excluded differences in 
the relative risk exceeding 20% in favour of PCI and 33% in 
favour of conservative treatment. There was also no overall 
difference in the risk for PCI during follow-up.
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S U B G R O U P  A N A L Y S E S
D O C U M E N T E D  I S C H E M I A
Subgroup analyses (Table 3) produced no evidence that 
trials with definitive documentation of ischemia by exercise 
test and/or scintigraphy had different risk ratios compared 
with trials where functional ischemia was not as thoroughly 
documented (Table 3).
E F F E C T  O F  S T E N T S
The availability or not of stents also did not make any 
substantial difference for any of the 5 considered endpoints. 
Several of these trials were conducted in the time period before 
stents were routinely introduced in clinical practice. However, 
our meta-analysis found no evidence of superiority for the PCI 
strategy, even when analyses were limited to trials using stents. 
Finally, the impact of drug-eluting stents cannot be predicted, 
but the currently available data suggest that they may not offer 
any benefits besides reducing the need for revascularization, 
while the risk of death and MI is not affected.21
R E C E N T  M Y O C A R D I A L  I N FA R C T I O N
The two trials that enrolled exclusively patients with rela-
tively recent MI17,18 showed a statistically significant reduction 
in the risk of death (p=0.037) and in the risk for subsequent 
PCI (p=0.029) and possibly also CABG (p=0.12) in the PCI 
arms. This subgroup differed significantly vs. the remaining 
trials for death and PCI risk ratios. Thus, PCI may actually 
be more effective in reducing the risk of death especially in 
trials where all patients had a relatively recent MI. Longer 
follow-up and additional data would be useful before making 
FIGURE 1. Comparison of percutaneous coronary intervention (PCI) vs. conservative medical treatment for (a) death, and (b) non-
fatal myocardial infarction. Each study is shown by its name along with the point estimate of the risk ratio and the respective 95% 
confidence intervals. In each panel, the size of the box denoting the point estimate in each study is proportional to the weight of the 
study. Also shown are the summary risk ratio and 95% confidence intervals according to the DerSimonian and Laird random effects 
model. [Adapted from Katritsis et al (reference 5)].
TABLE 2. Summary Risk Ratios for Major Outcomes with PCI vs. Conservative Medical Treatment
Outcome RE Risk Ratio (95% CI) p-value FE Risk Ratio (95% CI) p-value
Death 0.94 (0.72-1.24) 0.68 0.95 (0.72-1.23) 0.68
Cardiac death or MI 1.17 (0.88-1.57) 0.28 1.16 (0.91-1.48) 0.24
Non-fatal MI 1.28 (0.94-1.75) 0.12 1.32 (0.97-1.79) 0.077
CABG 1.03 (0.80-1.33) 0.82 1.04 (0.81-1.34) 0.76
PCI 1.23 (0.80-1.90) 0.34 0.91 (0.77-1.07) 0.25
CABG: coronary artery bypass grafting; CI= confidence intervals; FE: fixed effects; MI: myocardial infarction; PCI: percutaneous coronary 
intervention; RE: random effects
Adapted from Katritsis et al (reference 5).
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a strong recommendation for using PCI in this setting, since 
data are driven largely by a single trial (ALKK).
P R O C E D U R E - R E L A T E D  M Y O C A R D I A L 
I N FA R C T I O N
We observed a trend for increased risk of MI in patients 
undergoing PCI. This may reflect also the risk carried by the 
invasive procedure per se. Data were not consistently available 
across these trials to separate procedure-related infarctions 
from subsequent MI. Additionally, micro-infarcts caused in a 
considerable proportion of patients undergoing PCI may have 
adverse prognostic importance in the long-term.22
C O R O N A R Y  A R T E R Y  B Y PA S S  G R A F T I N G
The early literature suggested that PCI may cause an 
increased need for CABG.4 We found no evidence for any 
increased need of CABG in the PCI strategy as compared 
with the conservative strategy.
I N T E N S E  M E D I C A L  T H E R A P Y
The included trials did not routinely use the full spectrum 
of conservative interventions currently available for CAD 
management. Interestingly, excellent results for the conserva-
tive arm were obtained in a trial where special emphasis was 
placed on exercise, although it should be acknowledged that 
weekly counselling was also provided to patients in the exer-
cise group.19 Exercise may be unjustifiably under-utilized in 
current clinical practice.23 Moreover, the advent of statins has 
improved the treatment and outcomes of patients with chronic 
CAD with or without significant hypercholesterolemia.24 This 
potential benefit was not available in any of the early trials. 
In view of current recommendations the angioplasty-treated 
group in the AVERT trial had inadequate control of their lip-
ids. Overall, the different and potentially suboptimal medical 
management across the discussed trials is a limitation for un-
equivocal conclusions. However, one would expect even better 
outcomes, if medical management were indeed optimized.
C O N C L U S I O N S
In patients with chronic coronary artery disease and 
good left ventricular function, PCI does not confer any clear 
benefit in terms of hard long-term clinical outcomes, such as 
mortality, myocardial infarction or the need for subsequent 
revascularization, as compared with medical conservative 
treatment. Evidence-based indications of PCI in this setting 
include relief of symptoms and recent myocardial infarction. 
At the same time, the early fear of increased need for revascu-
larization after PCI is probably not warranted. By comparing 
the benefits against cost considerations, it seems that many 
percutaneous interventions that are currently performed in 
patients with non-acute CAD are probably not justified.
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